73 related articles for article (PubMed ID: 3434494)
1. [The evaluation of chemotherapy of relapse in prostatic cancer with new response criteria].
Isaka S; Fuse H; Akaza H; Moriyama N; Usami M; Kotake T; Matsumura Y; Imai K; Yamanaka H; Matsumoto K
Hinyokika Kiyo; 1987 Sep; 33(9):1389-95. PubMed ID: 3434494
[TBL] [Abstract][Full Text] [Related]
2. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
3. Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the time of relapse.
González-Barcena D; Schally AV; Vadillo-Buenfil M; Cortez-Morales A; Hernández L V; Cardenas-Cornejo I; Comaru-Schally AM
Prostate; 2003 Aug; 56(3):183-91. PubMed ID: 12772187
[TBL] [Abstract][Full Text] [Related]
4. [Response criteria for prostatic cancer treated by chemotherapy or antiandrogenic therapy].
Akaza H; Usami M; Kotake T; Matsumura Y; Moriyama N; Imai K; Fuse H; Isaka S; Yamanaka H; Matsumoto K
Hinyokika Kiyo; 1987 Jun; 33(6):894-904. PubMed ID: 3673839
[TBL] [Abstract][Full Text] [Related]
5. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
Hussain M; Tangen CM; Lara PN; Vaishampayan UN; Petrylak DP; Colevas AD; Sakr WA; Crawford ED;
J Clin Oncol; 2005 Dec; 23(34):8724-9. PubMed ID: 16314632
[TBL] [Abstract][Full Text] [Related]
6. [Treatment for hormone-refractory or relapsing prostatic cancer].
Hirao Y; Ozono S; Okajima E
Gan To Kagaku Ryoho; 1996 Mar; 23(4):418-26. PubMed ID: 8678492
[TBL] [Abstract][Full Text] [Related]
7. [Transarterial chemoperfusion of the pelvis--results in symptomatic locally recurrent tumors and lymph node metastases].
Vogl TJ; Zangos S; Eichler K; Balzer JO; Jacob U; Keilhauer R; Bauer RW
Rofo; 2007 Nov; 179(11):1174-80. PubMed ID: 17805998
[TBL] [Abstract][Full Text] [Related]
8. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
[TBL] [Abstract][Full Text] [Related]
9. [The significance of prostatic serum acid phosphatase as a tumor marker in prostatic cancer].
Hamami G
Hinyokika Kiyo; 1983 Oct; 29(10):1231-45. PubMed ID: 6085711
[TBL] [Abstract][Full Text] [Related]
10. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
[TBL] [Abstract][Full Text] [Related]
11. [Serum alkaline phosphatase flare in prostate cancer accompanied by bone metastases and treated with hormonal therapy. TEKK Study Group].
Taue R; Kanayama H; Kagawa S
Hinyokika Kiyo; 1999 Oct; 45(10):681-5. PubMed ID: 10586358
[TBL] [Abstract][Full Text] [Related]
12. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
13. A multicenter phase II trial of losoxantrone (DuP-941) in hormone-refractory metastatic prostate cancer.
Huan SD; Natale RB; Stewart DJ; Sartiano GP; Stella PJ; Roberts JD; Symes AL; Finizio M
Clin Cancer Res; 2000 Apr; 6(4):1333-6. PubMed ID: 10778959
[TBL] [Abstract][Full Text] [Related]
14. Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity.
Miglietta L; Cannobbio L; Boccardo F
Anticancer Res; 1995; 15(6B):2825-8. PubMed ID: 8669872
[TBL] [Abstract][Full Text] [Related]
15. Survival after cytotoxic chemotherapy in patients with advanced hormone-resistant prostate cancer: a phase II study.
Stathopoulos GP; Koutantos J; Vaslamatzis MM; Athanasiadis A; Papadopoulos G; Labrodimou G; Stathopoulos J; Rigatos S
Oncol Rep; 2009 Aug; 22(2):345-8. PubMed ID: 19578775
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
Lara PN; Stadler WM; Longmate J; Quinn DI; Wexler J; Van Loan M; Twardowski P; Gumerlock PH; Vogelzang NJ; Vokes EE; Lenz HJ; Doroshow JH; Gandara DR
Clin Cancer Res; 2006 Mar; 12(5):1556-63. PubMed ID: 16533781
[TBL] [Abstract][Full Text] [Related]
17. Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer.
Ansari MS; Gupta NP
Urol Oncol; 2004; 22(5):415-20. PubMed ID: 15464923
[TBL] [Abstract][Full Text] [Related]
18. [Effect of estramustine phosphate on hormone refractory prostate cancer].
Tanaka M; Shiomi K; Hamano S; Suzuki N; Igarashi T; Murakami S; Shimazaki J
Hinyokika Kiyo; 1997 Mar; 43(3):245-50. PubMed ID: 9127765
[TBL] [Abstract][Full Text] [Related]
19. A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.
Maki RG; Kraft AS; Scheu K; Yamada J; Wadler S; Antonescu CR; Wright JJ; Schwartz GK
Cancer; 2005 Apr; 103(7):1431-8. PubMed ID: 15739208
[TBL] [Abstract][Full Text] [Related]
20. [Combined hormone and chemotherapy for the patients with advanced prostate cancer].
Uekado Y; Hirano A; Inagaki T; Hiroi A; Watanabe T
Gan To Kagaku Ryoho; 1995 Jul; 22(8):1041-5. PubMed ID: 7611755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
